Guidant Shareholders To Vote On J&J Offer; Boston Scientific Still Interested
This article was originally published in The Gray Sheet
Executive Summary
Guidant's board of directors has formally endorsed Johnson & Johnson's $21.5 bil. takeover bid while simultaneously agreeing to enter into discussions with Boston Scientific on its $25 bil. competing offer
You may also be interested in...
Boston Scientific CRM audit
Firm anticipates FDA inspections of cardiac rhythm management facilities impacted by a December 2005 warning letter to Guidant to begin in the "coming weeks," CEO Jim Tobin said Oct. 18 during the firm's third-quarter earnings call (1"The Gray Sheet" Jan. 2, 2006, p. 3). The company is "ready," he says...
Boston Scientific CRM audit
Firm anticipates FDA inspections of cardiac rhythm management facilities impacted by a December 2005 warning letter to Guidant to begin in the "coming weeks," CEO Jim Tobin said Oct. 18 during the firm's third-quarter earnings call (1"The Gray Sheet" Jan. 2, 2006, p. 3). The company is "ready," he says...
FDA Finds Another Example Of Quality Control Problems At Guidant
A recent FDA inspection of Guidant's cardiac rhythm management facilities in St. Paul resulted in one new observation about a potential quality control problem at the site, the company reported Feb. 23
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: